What we're working on, thinking about and speaking on.

Generating the evidence medtech needs for NHS Drug Tariff Part IX

Part IX is being reformed. Under the new Enhanced Assessment Framework, every wound and skin care product — new listing or renewal — will be scored out of 100 on quality, social value and price. The quality evidence has the longest lead time, and it has to be gathered, analysed and written up before you can apply. We build that evidence base before the window opens, mapped directly to NHSBSA's scoring criteria.